CXBS (Corix Bioscience) EPS without NRI: $-0.47 (TTM As of Sep. 2017)


What is Corix Bioscience EPS without NRI?

Corix Bioscience CXBS -99.00% EPS without NRI is $-0.47 as of Sep. 2017.

Corix Bioscience's earnings per share without non-recurring items for the three months ended in Sep. 2017 was $-0.03. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.47.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Corix Bioscience's EPS without NRI or its related term are showing as below:

CXBS's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Corix Bioscience's EPS (Diluted) for the three months ended in Sep. 2017 was $-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.29.

Corix Bioscience's EPS (Basic) for the three months ended in Sep. 2017 was $-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.29.


Corix Bioscience  (OTCPK:CXBS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Corix Bioscience EPS without NRI Related Terms


Corix Bioscience EPS without NRI Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience EPS without NRI Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
EPS without NRI
Get a 7-Day Free Trial -914,728.68 -21,395.35 -12,170.54 -0.80 -0.50

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.39 -0.01 -0.04 -0.03

CXBS vs BKIT, YBAO, HSTI: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corix Bioscience PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's PE Ratio without NRI falls into.



Corix Bioscience EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.47 mean?
Corix Bioscience (CXBS) has a EPS without NRI of $-0.47 as of Sep. 2017. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's EPS without NRI too high?
Corix Bioscience's current EPS without NRI is $-0.47.
How does Corix Bioscience's EPS without NRI compare to BKIT and YBAO?
Corix Bioscience's EPS without NRI of $-0.47 can be compared against companies in the Drug Manufacturers industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Corix Bioscience and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corix Bioscience's current EPS without NRI is $-0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current EPS without NRI of $-0.47. The current EPS without NRI is $-0.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current EPS without NRI is $-0.47 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.